Dr Philippe Rogueda
Co-Founder & Chief Business Officer

Is this your profile?

About

Philippe Rogueda, PhD, Co-Founder and Chief Business Officer of Merxin, is a Fellow of the Royal Society of Chemistry and orally inhaled and nasal drug product expert with an accomplished track record delivering technology and global projects across R&D and commercial industrialisation. Dr Rogueda has held a number of positions in the inhaled drug delivery field, starting as a formulation scientist in the pMDI formulation labs of AstraZeneca; as a principal scientist at Novartis designing DPI, nasal and nebulised inhaled therapies; as an Executive Director of Inhaled Products R&D at Actavis/TEVA; before founding Merxin to make inhaler technology
accessible to a wider audience. Dr Rogueda is Principal Consultant at Aedestra, founder of the Inhalation Asia conference, and of Anthocan a company dedicated to the formulating of inhaled cannabis therapies.

Contributions

SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES

Zaid Aqrawe, Philippe Rogueda, Darragh Murnane and Bryan Eng, discuss the opportunity presented by soft mist inhalers as an alternative delivery device to nebulisers for inhaled therapies, contrasting the two device categories across multiple factors.

More contributions

DELIVERING BIOLOGICS WITH SOFT MIST INHALERS – A MARKET POISED TO EXPAND

Philippe Rogueda discusses the inhalable biologics market, how the introduction of soft mist inhalers represents a significant opportunity for new and old therapeutics alike, and how the market is poised for a major expansion in therapeutic application, size and value.

OFF-THE-SHELF OR CUSTOM-MADE? CHOOSING A DRY POWDER INHALER

Philippe Rogueda discusses the manifold factors that need to be taken into account when choosing a dry powder inhaler – beyond just the target disease, formulation and patient population.

PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS

Igor Gonda, David Cipolla and Philippe Rogueda discuss the changes needed to increase the number of approved generic orally inhaled drug products (OIDPs) whilst providing additional incentives to innovators to meet the needs of the general public.

Top